Generalized Anxiety Disorder

name: Generalized Anxiety Disorder
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-02-17T21:53:14Z'
category: Complex
parents:
- Psychiatric Disease
disease_term:
  preferred_term: generalized anxiety disorder
  term:
    id: MONDO:0001942
    label: generalized anxiety disorder
pathophysiology:
- name: Amygdala Hyperactivity
  description: >
    Exaggerated amygdala response to perceived threats leads to
    excessive fear and anxiety. Reduced prefrontal cortex regulation
    of amygdala activity.
  cell_types:
  - preferred_term: Amygdala Pyramidal Neuron
    term:
      id: CL:4023110
      label: amygdala pyramidal neuron
  biological_processes:
  - preferred_term: Fear Response
    term:
      id: GO:0042596
      label: fear response
  evidence:
  - reference: PMID:38865810
    supports: PARTIAL
    snippet: "Evidence indicates that anxiety disorders arise from an imbalance in
      the functioning of brain circuits that govern the modulation of emotional responses
      to possibly threatening stimuli. The circuits under consideration in this context
      include the amygdala's bottom-up activity, which signifies the existence of
      stimuli that may be seen as dangerous. Moreover, these circuits encompass top-down
      regulatory processes that originate in the prefrontal cortex, facilitating the
      communication of the emotional significance associated with the inputs."
    explanation: This evidence supports the model of amygdala hyperactivity in
      anxiety and the role of prefrontal cortex in regulating amygdala responses
      to threat stimuli.
- name: GABA System Dysfunction
  description: >
    Reduced GABAergic inhibition contributes to neuronal hyperexcitability
    and anxiety. Benzodiazepines enhance GABA function.
  cell_types:
  - preferred_term: GABAergic Interneuron
    term:
      id: CL:0011005
      label: GABAergic interneuron
  biological_processes:
  - preferred_term: GABAergic Transmission
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
  evidence:
  - reference: PMID:38865810
    supports: PARTIAL
    snippet: "A decrease in GABAergic activity is present in both anxiety disorders
      and severe depression. Research on cerebral functional imaging in depressive
      individuals has shown reduced levels of GABA within the cortical regions. Additionally,
      animal studies demonstrated that a reduction in the expression of GABAA/B receptors
      results in a behavioral pattern resembling anxiety."
    explanation: This evidence demonstrates reduced GABAergic activity in
      anxiety disorders through both imaging studies and animal models showing
      that decreased GABA receptor expression leads to anxiety-like behavior.
  - reference: PMID:38865810
    supports: PARTIAL
    snippet: "The amygdala consists of inhibitory networks composed of GABAergic interneurons,
      responsible for modulating anxiety responses in both normal and pathological
      conditions. The GABAA receptor has allosteric sites (e.g., α/γ, γ/β, and α/β)
      which enable regulation of neuronal inhibition in the amygdala. These sites
      serve as molecular targets for anxiolytic medications such as benzodiazepine
      and barbiturates."
    explanation: This supports the mechanism of GABAergic dysfunction in the
      amygdala and explains how benzodiazepines work by targeting GABAA receptor
      allosteric sites to enhance inhibition.
  - reference: PMID:39294497
    supports: NO_EVIDENCE
    snippet: "We leveraged information from more than 1.2 million participants, including
      97,383 cases, to investigate the genetics of anxiety disorders across five continental
      groups. Through ancestry-specific and cross-ancestry genome-wide association
      studies, we identified 51 anxiety-associated loci, 39 of which were novel."
    explanation: This snippet supports broad genetic architecture of anxiety
      disorders but does not directly provide evidence for GABA system
      dysfunction.
- name: Serotonin Dysregulation
  description: >
    Altered serotonin signaling, particularly in raphe-prefrontal
    circuits, contributes to anxiety. SSRIs are first-line treatment.
  cell_types:
  - preferred_term: Serotonergic Neuron
    term:
      id: CL:0000850
      label: serotonergic neuron
  biological_processes:
  - preferred_term: Serotonin Signaling
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  evidence:
  - reference: PMID:24936175
    supports: PARTIAL
    snippet: "Decreased serotonergic activity has been implicated in anxiety and major
      depression, and antidepressants directly or indirectly increase the long-term
      activity of the serotonin system. A key component of serotonin circuitry is
      the 5-HT1A autoreceptor, which functions as the major somatodendritic autoreceptor
      to negatively regulate the 'gain' of the serotonin system."
    explanation: This evidence establishes the role of decreased serotonergic
      activity in anxiety and explains how antidepressants work by increasing
      serotonin system activity.
  - reference: PMID:24936175
    supports: PARTIAL
    snippet: "In addition, 5-HT1A heteroreceptors are abundantly expressed post-synaptically
      in the prefrontal cortex (PFC), amygdala, and hippocampus to mediate serotonin
      actions on fear, anxiety, stress, and cognition."
    explanation: This supports the specific role of serotonin signaling in
      prefrontal-limbic circuits that regulate anxiety and fear responses.
- name: HPA Axis Dysregulation
  description: >
    Chronic activation of the stress response system with elevated
    cortisol contributes to sustained anxiety and physical symptoms.
  biological_processes:
  - preferred_term: Stress Response
    term:
      id: GO:0006950
      label: response to stress
  evidence:
  - reference: PMID:20808146
    supports: SUPPORT
    snippet: "Generalized anxiety disorder (GAD) is a common disorder in older adults,
      which has been linked to hyperactivity of the hypothalamic-pituitary-adrenal
      (HPA) axis in this age group."
    explanation: This evidence directly links GAD to HPA axis hyperactivity,
      particularly in older adults.
  - reference: PMID:20808146
    supports: SUPPORT
    snippet: "Compared with placebo-treated patients, SSRI-treated patients had a
      significantly greater reduction in both peak and total cortisol. This reduction
      in cortisol was limited to patients with elevated (above the median) baseline
      cortisol, in whom SSRI-treated patients showed substantially greater reduction
      in cortisol than did placebo-treated patients. Reductions in cortisol were associated
      with improvements in anxiety."
    explanation: This demonstrates that HPA axis hyperactivity with elevated
      cortisol is present in GAD patients and that successful treatment reduces
      cortisol levels in parallel with anxiety symptom reduction.
- name: Noradrenergic Hyperactivity
  description: >
    Elevated norepinephrine activity in locus coeruleus contributes
    to hyperarousal and somatic symptoms of anxiety.
  cell_types:
  - preferred_term: Noradrenergic Neuron
    term:
      id: CL:0008025
      label: noradrenergic neuron
- name: Oxidative Stress
  description: >
    Increased oxidative stress markers and reduced antioxidant enzyme
    activity in GAD patients. Elevated malondialdehyde and reduced
    superoxide dismutase correlate with symptom severity.
  evidence:
  - reference: PMID:38204917
    supports: SUPPORT
    snippet: "The 8-OHdG values of the GAD group were determined to be statistically
      significantly higher than those of the control group (p=0.028)."
    explanation: This demonstrates elevated oxidative DNA damage in GAD patients
      as measured by 8-hydroxy-2-deoxyguanosine (8-OHdG), a marker of oxidative
      stress.
  - reference: PMID:38204917
    supports: SUPPORT
    snippet: "The results of this study showed that there could be DNA damage because
      of oxidative stress in GAD patients."
    explanation: This concludes that oxidative stress contributes to the
      pathophysiology of GAD through DNA damage mechanisms.
- name: Epigenetic Alterations
  description: >
    DNA methylation changes in anxiety-related genes, particularly in
    monocytes and granulocytes. Methylation sites identified in genes
    involved in neurogenesis and fear memory.
  cell_types:
  - preferred_term: Monocyte
    term:
      id: CL:0000576
      label: monocyte
  - preferred_term: Granulocyte
    term:
      id: CL:0000094
      label: granulocyte
  evidence:
  - reference: PMID:37542162
    supports: PARTIAL
    snippet: "Applying an enrichment-based sequencing approach covering nearly 28
      million autosomal CpG sites, we conducted a methylome-wide association study
      (MWAS) of lifetime ANX in 1132 participants (618 cases/514 controls) from the
      Netherlands Study of Depression and Anxiety. Using epigenomic deconvolution,
      we performed MWAS for the main cell types in blood: granulocytes, T-cells, B-cells
      and monocytes. Cell-type specific analyses identified 280 and 82 methylome-wide
      significant associations (q-value < 0.1) in monocytes and granulocytes, respectively."
    explanation: This large-scale epigenome-wide study identifies hundreds of
      significant DNA methylation sites associated with anxiety disorders,
      supporting the role of epigenetic mechanisms in GAD pathophysiology.
  - reference: PMID:37542162
    supports: PARTIAL
    snippet: "In monocytes, two specific sites in the FZR1 gene showed significant
      replication after Bonferroni correction with an additional 15 nominally replicated
      sites in monocytes and 4 in T-cells. FZR1 regulates neurogenesis in the hippocampus,
      and its knockout leads to impairments in associative fear memory and long-term
      potentiation in mice."
    explanation: This identifies FZR1 as a key gene with replicable methylation
      changes in anxiety, linking epigenetic alterations to hippocampal
      neurogenesis and fear memory mechanisms.
phenotypes:
- name: Excessive Worry
  category: Psychiatric
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Persistent, difficult to control
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:39294497
    supports: NO_EVIDENCE
    snippet: "The heritability of anxiety was enriched for genes expressed in the
      limbic system, cerebral cortex, cerebellum, metencephalon, entorhinal cortex
      and brain stem."
    explanation: This snippet supports genetic architecture of anxiety disorders
      but does not directly evidence the specific clinical phenotype of
      excessive worry.
- name: Restlessness
  category: Psychiatric
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Restlessness
    term:
      id: HP:0000711
      label: Restlessness
- name: Fatigue
  category: Systemic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- name: Difficulty Concentrating
  category: Neurological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Poor Concentration
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
- name: Muscle Tension
  category: Musculoskeletal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Muscle Tension
    term:
      id: HP:0003552
      label: Muscle stiffness
- name: Sleep Disturbance
  category: Psychiatric
  frequency: FREQUENT
  notes: Difficulty falling or staying asleep
  phenotype_term:
    preferred_term: Insomnia
    term:
      id: HP:0002360
      label: Sleep disturbance
- name: Irritability
  category: Psychiatric
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
biochemical:
- name: Cortisol
  presence: Elevated
  context: Chronic stress activation
- name: GABA
  presence: Decreased
  context: Reduced inhibitory tone
genetic:
- name: SLC6A4
  association: Risk Factor
  notes: Serotonin transporter
- name: COMT
  association: Risk Factor
  notes: Catecholamine metabolism
- name: CRHR1
  association: Risk Factor
  notes: CRH receptor
- name: NPY
  association: Risk Factor
  notes: Neuropeptide Y
environmental:
- name: Childhood Adversity
  notes: Major risk factor
- name: Chronic Stress
  notes: Precipitates and maintains
- name: Trauma
  notes: Can trigger onset
- name: Caffeine
  notes: Can exacerbate symptoms
treatments:
- name: SSRIs
  description: First-line pharmacotherapy (escitalopram, sertraline,
    paroxetine).
- name: SNRIs
  description: Alternative first-line (venlafaxine, duloxetine).
- name: Buspirone
  description: Non-benzodiazepine anxiolytic, no dependence risk.
- name: Benzodiazepines
  description: Short-term use for severe symptoms, dependence risk.
- name: Pregabalin
  description: Effective in GAD, approved in Europe.
- name: Cognitive Behavioral Therapy
  description: First-line psychotherapy, addresses worry and avoidance.
- name: Relaxation Training
  description: Progressive muscle relaxation, breathing exercises.
- name: Mindfulness-Based Therapy
  description: Reduces worry and rumination.
classifications:
  harrisons_chapter:
  - classification_value: psychiatric disorder
datasets:
references:
- reference: DOI:10.1002/wps.21078
  title: 'Candidate biomarkers in psychiatric disorders: state of the field'
  findings: []
- reference: DOI:10.1038/s41380-023-02205-w
  title: Methylome-wide association study of anxiety disorders
  findings: []
- reference: DOI:10.1038/s41588-024-01908-2
  title: Gene discovery and biological insights into anxiety disorders from a
    large-scale multi-ancestry genome-wide association study
  findings: []
- reference: DOI:10.1038/s41598-025-90362-z
  title: The power spectrum and functional connectivity characteristics of
    resting-state EEG in patients with generalized anxiety disorder
  findings: []
- reference: DOI:10.1101/2024.07.03.24309466
  title: Genome-wide association study of major anxiety disorders in 122,341
    European-ancestry cases identifies 58 loci and highlights GABAergic
    signaling
  findings: []
- reference: DOI:10.1101/2024.09.07.24313247
  title: Oxidative stress markers predict treatment outcomes in patients with
    generalized anxiety disorder treated with selective serotonin reuptake
    inhibitors
  findings: []
- reference: DOI:10.3390/ijms26115417
  title: 'Molecular Basis of Anxiety: A Comprehensive Review of 2014–2024 Clinical
    and Preclinical Studies'
  findings: []
- reference: DOI:10.3390/nu16203564
  title: 'Effect of Probiotics Supplementation on Cortisol Levels: A Systematic Review
    and Meta-Analysis'
  findings: []
- reference: DOI:10.3758/s13415-024-01162-3
  title: Understanding the heterogeneity of anxiety using a translational
    neuroscience approach
  findings: []
- reference: DOI:10.4236/psych.2023.141003
  title: 'Generalized Anxiety Disorder: A Review of Current Literature in Saudi Arabia'
  findings: []